Mar 13, 2025 4:07pm EDT Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Jan 28, 2025 8:00am EST Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
